EGS Tools Used in About 1,500 Natural Orifice Surgeries

REDWOOD CITY, Calif. — Leaders of EndoGastric Solutions (EGS) recently announced that their surgical devices have been used in almost 1,500 incisionless natural orifice surgeries (NOS) in the United States, Europe and Brazil.

NOS are gaining momentum, said Thierry Thaure, president and CEO of EndoGastric Solutions.

“Millions of patients worldwide can benefit from these incisionless surgical procedures. EGS has seen procedure volume double in the last few months, and we anticipate continued dramatic growth over the next few years,” Thaure said in a press release.

EGS has developed a proprietary NOS platform technology. StomaphyX and EsophyX are designed for performing incisionless reconstructive gastrointestinal procedures. The devices are introduced into the body through the mouth, rather than through an abdominal incision.

The advantages of incisionless surgery over laparoscopic or open surgery include shorter hospital stay, reduced patient discomfort, shortened patient recovery, no visible scars, and typically higher patient satisfaction, according to EGS.

With StomaphyX, under visual guidance of an endoscope, small sections of the stomach wall are suctioned into the device and fastened with permanent suture-like fasteners to create multiple large tissue folds, or plications. Multiple plications can be created depending on the needs of the patient.

According to the press release, the EsophyX TIF procedure reconstructs a robust antireflux barrier at the gastroesophageal junction using a similar procedure that restores natural anatomical geometry to effectively treat Gastroesophageal Reflux Disease (GERD).

EGS is a privately held corporation located in Redmond, Wash., and Redwood City, Calif. EGS develops incisionless transoral procedures for the treatment of upper gastrointestinal conditions, including gastroesophageal reflux disease (GERD) and other GI conditions.

For more information about EGS, click here.